Generex Biotechnology Corp (GNBT) - Financial and Strategic SWOT Analysis Review

Generex Biotechnology Corp (GNBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by it to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The companys proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using its proprietary RapidMist device. Generex through its subsidiary, Antigen Express, has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations for the treatment of infectious, malignant, allergic, and autoimmune diseases. Generex is headquartered in Miramar, Florida, the US.

Generex Biotechnology Corp Key Recent Developments

Nov 29,2018: Generex to acquire 51% stake in Olaregen Therapeutix
Nov 15,2018: Generex announces appointment of executive management team
Oct 29,2018: Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda ) for the Treatment of Triple-Negative Breast Cancer
Oct 17,2018: Generex Announces Launch of NuGenerex Distribution Solutions
Oct 12,2018: Generex announces Anthony S. Crisci, Esq., CPA as general manager, chief compliance officer and corporate counsel of its new, wholly-owned subsidiary, NuGenerex distribution solutions

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Generex Biotechnology Corp - Key Facts 6
Generex Biotechnology Corp - Key Employees 7
Generex Biotechnology Corp - Key Employee Biographies 8
Generex Biotechnology Corp - Major Products and Services 9
Generex Biotechnology Corp - History 10
Generex Biotechnology Corp - Company Statement 13
Generex Biotechnology Corp - Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 Company Analysis 16
Company Overview 16
Generex Biotechnology Corp - Business Description 17
Generex Biotechnology Corp - SWOT Analysis 18
SWOT Analysis - Overview 18
Generex Biotechnology Corp - Strengths 18
Generex Biotechnology Corp - Weaknesses 19
Generex Biotechnology Corp - Opportunities 20
Generex Biotechnology Corp - Threats 21
Generex Biotechnology Corp - Key Competitors 22
Section 3 Company Financial Ratios 23
Financial Ratios - Capital Market Ratios 23
Financial Ratios - Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios - Interim Ratios 27
Financial Ratios - Ratio Charts 28
Section 4 Companys Lifesciences Financial Deals and Alliances 29
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
Generex Biotechnology Corp, Recent Deals Summary 31
Section 5 Companys Recent Developments 32
Nov 29, 2018: Generex to acquire 51% stake in Olaregen Therapeutix 32
Nov 15, 2018: Generex announces appointment of executive management team 33
Oct 29, 2018: Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda ) for the Treatment of Triple-Negative Breast Cancer 35
Oct 29, 2018: Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda ) for the Treatment of Triple-Negative Breast Cancer 37
Oct 17, 2018: Generex Announces Launch of NuGenerex Distribution Solutions 39
Oct 17, 2018: Generex Announces Launch of NuGenerex Distribution Solutions 40
Oct 17, 2018: Generex Announces Launch of NuGenerex Distribution Solutions 41
Oct 12, 2018: Generex announces Anthony S. Crisci, Esq., CPA as general manager, chief compliance officer and corporate counsel of its new, wholly-owned subsidiary, NuGenerex distribution solutions 42
Oct 05, 2018: Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program 43
Oct 05, 2018: Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program 46
Section 6 Appendix 49
Methodology 49
Ratio Definitions 49
About GlobalData 53
Contact Us 53
Disclaimer 53

List Of Tables


Generex Biotechnology Corp, Key Facts 6
Generex Biotechnology Corp, Key Employees 7
Generex Biotechnology Corp, Key Employee Biographies 8
Generex Biotechnology Corp, Major Products and Services 9
Generex Biotechnology Corp, History 10
Generex Biotechnology Corp, Subsidiaries 15
Generex Biotechnology Corp, Key Competitors 22
Generex Biotechnology Corp, Ratios based on current share price 23
Generex Biotechnology Corp, Annual Ratios 24
Generex Biotechnology Corp, Annual Ratios (Cont...1) 25
Generex Biotechnology Corp, Interim Ratios 27
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30
Generex Biotechnology Corp, Recent Deals Summary 31
Currency Codes 49
Capital Market Ratios 49
Equity Ratios 50
Profitability Ratios 50
Cost Ratios 51
Liquidity Ratios 51
Leverage Ratios 52
Efficiency Ratios 52

List Of Figures


Generex Biotechnology Corp, Performance Chart (2014 - 2018) 26
Generex Biotechnology Corp, Ratio Charts 28
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29
Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

Generex Biotechnology Corp (GNBT) - Financial and Strategic SWOT Analysis Review

Generex Biotechnology Corp (GNBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

Generex Biotechnology Corporation Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Generex Biotechnology Corporation Company Profile is a detailed strategic and analytical report on Generex Biotechnology Corporation. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Medigen Biotechnology Corporation Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Medigen Biotechnology Corporation Company Profile is a detailed strategic and analytical report on Medigen Biotechnology Corporation. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Golden Biotechnology Corp Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Golden Biotechnology Corp Company Profile is a detailed strategic and analytical report on Golden Biotechnology Corp. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available